Answers are grounded in this paper and cite their sources.
Case report describes immune encephalitis following Tirelizumab in a lung cancer patient, highlighting the growing risk of adverse drug reactions from immune checkpoint inhibitors.
In the contemporary landscape of oncology, immune checkpoint blockade therapy has emerged as a paramount therapeutic modality. However, concomitant with the pervasive deployment of immune checkpoint inhibitors (ICIs), there has been an escalating incidence of adverse drug reactions over the years. Immunological encephalitis, a prevalent form of central nervous system toxicity, poses a significant threat to the lives of affected patients. A 65‐year‐old male patient, diagnosed with squamous cell carcinoma of the lung, experienced an atypical immune‐mediated encephalitis of clinical nature after the administration of a PD‐1 inhibitor, specifically Tirelizumab. The present investigation delved into the clinical presentations and suitable therapeutic protocols for immune‐mediated encephalitis.
No takes yet. Share an insight, caveat, or question.
Hao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: